AR and melanoma: To assess whether targeting of AR in BRAFi-resistant melanoma cells elicits opposite effects, we treated primary and established melanoma cells with two different AR inhibitors; AZD3514, suppressing AR activity through both ligand competitive and non-competitive mechanisms34, and ARCC4 causing PROTAC-mediated degradation26.